You are here

  • Professor Theresa Reineke

    Professor Reineke co-organizes special issue of Bioconjugate Chemistry

Focuses on therapeutic innovation

Cover for Professor Reineke's work on special edition of Bioconjugate Chemistry focused on therapeutic innovations.

Professor Theresa Reineke has served as a guest co-editor and co-organizer for a special issue of Bioconjugate Chemistry focused on, "Delivery of Proteins and Nucleic Acids: Achievements and Challenges," which was published on February 20, 2019.

To introduce the special issue, Reineke also coauthored an editorial focusing on why therapeutic innovation has been important to her personally and professionally, including the creation of drugs that are less toxic and more targeted, and gene therapy strategies. Her editorial co-organizers and co-authors are Professor Ronald Raines from the Massachusetts Institute of Technology, and Professor Vincent Rotello, editor-in-chief of Bioconjugate Chemistry from the University of Massachusetts Amherst.

Reineke is a leading researcher in the fields of polymer chemistry, drug delivery, and gene therapy. Her research group members specialize in the synthetic design, chemical characterization, and biological study of designer macromolecules. Her research group seeks to discover novel delivery vehicles for nucleic acids and drugs, elucidate cellular-level mechanisms of biomaterial function, and impart enhanced material performance through the use of sustainable feedstocks. The special issue features publications by a number of leading researchers working to make the field of biologic drugs more widely applicable for numerous diseases on the global scale.

Professor Reineke's contribution to the special edition focuses on fast, efficient, and inexpensive methods for delivering functional nucleic acids to create primary human cell therapies. The article is entitled, “Molecular Additives Significantly Enhance Glycopolymer-Mediated Transfection of Large Plasmids and Functional CRISPR-Cas9 Transcription Activation Ex Vivo in Primary Human Fibroblasts and Induced Pluripotent Stem Cells." This work was led by William Boyle, Ph.D., a recent graduate from the Reineke group and the University of Minnesota (UMN) Department of Chemistry. This work also features their collaboration with the laboratory of Professor Jakub Tolar, dean of the UMN Medical School and vice president for Clinical Affairs.